Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.60 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.57 |
| ▸ | TCF7 | P36402 | 2/20 | 0.57 |
| ▸ | BCL9 | O00512 | 1/20 | 0.57 |
| ▸ | TCF4 | P15884 | 1/20 | 0.57 |
| ▸ | CLPP | Q16740 | 1/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23813412 | 0.95 | CTNNB1 (0.58) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL23913418 | 0.95 | CTNNB1 (0.58) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL23913420 | 0.94 | CTNNB1 (0.63) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL25518222 | 0.94 | CTNNB1 (0.59) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL23913419 | 0.92 | CTNNB1 (0.59) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL23813445 | 0.92 | CTNNB1 (0.59) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL23813415 | 0.91 | CTNNB1 (0.57) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL23913416 | 0.91 | CTNNB1 (0.57) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL23813462 | 0.91 | CTNNB1 (0.57) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL25518224 | 0.91 | CTNNB1 (0.59) | CYP3A4CTNNB1TCF7BCL9TCF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20210317123-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3+2 PHARMA, LLC | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | CREBBP, CREB1, EP300 | CYP3A4 4402/4885CTNNB1 4/4885TCF7 44/4885 |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | CREBBP, CREB1, EP300 | CYP3A4 4402/4885CTNNB1 4/4885TCF7 44/4885 |
| US-20210317123-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | CREBBP, CREB1, EP300 | CYP3A4 4402/4885CTNNB1 4/4885TCF7 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.